Roche Holding, CH0012032048

Roche Holding stock gains as Ocrevus wins fresh EU backing

Published on 09/21/2026 at 15:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche Holding stock rose 1.4 percent to CHF 361.70 on September 21, 2026. Roche also reported CHF 31.28 billion in first-half 2026 sales and CHF 8.64 billion in net income.

Automatisches Diagnostik-Laborgerät mit Touchscreen-Oberfläche im klinischen Labor — Roche Holding AG CH0012032048 – Diagnostik-Analysegerät verarbeitet biologische Proben im modernen klinischen Labor, Illustration mit AI erstellt.

Roche Holding stock (ISIN CH0012032048) rose 1.4 percent to CHF 361.70 on September 21, 2026, with 83,829 shares traded by 12:28 p.m. on SIX SX. The latest catalyst came on September 18, 2026, when Roche said the European Medicines Agency's CHMP recommended approval of Ocrevus for children and adolescents with relapsing forms of multiple sclerosis.

Ocrevus keeps the pipeline visible

According to Globenewswire on September 18, 2026, the CHMP positive opinion covers Ocrevus intravenous infusion for patients aged 10 years and older, and Roche said the European Commission decision is expected in the near future. Roche also said the Phase III OPERETTA 2 study showed a 48 percent reduction in relapses versus fingolimod and reductions of 48 percent in new or enlarging T2 lesions and 87 percent in gadolinium-enhancing active T1 lesions.

The company also pointed to more than 525,000 adult patients globally in the product's safety base, which underlines why the drug matters beyond a single regulatory step. For investors, that mix of pediatric expansion and established adult use is the most concrete read-through from the September 18 release.

Half-year numbers stayed solid

According to MarketScreener, Roche reported CHF 31.28 billion in first-half 2026 net sales and CHF 8.64 billion in first-half 2026 net income, after CHF 30.94 billion and CHF 8.64 billion in the first half of 2025. MarketScreener also showed projected 2026 net sales of CHF 62.66 billion and projected 2026 net income of CHF 14.84 billion, with a 2026 EBITDA margin of 40.36 percent.

That leaves the 2026 earnings base looking broad rather than narrow: sales rose 1.1 percent year on year in the first half, while net income was unchanged at CHF 8.64 billion. The next figure that matters is whether the Ocrevus label expansion can translate into a faster operating mix later in the year.

Stock stays close to the range high

At the same SIX SX snapshot on September 21, 2026, Roche traded between CHF 359.00 and CHF 361.70, with volume at 83,829 shares and the SMI at 13,940 points in the background. The stock's 52-week range was CHF 252.20 to CHF 375.80, so the current level sits 3.8 percent below the high and 43.4 percent above the low.